Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

NCT04683237 · Withdrawn

Last updated 2026-05-28

This clinical trial is testing whether the combination of liraglutide (a diabetes medication) and megestrol acetate (a hormone therapy) can help reduce abnormal cell growth in the uterus of obese women with fertility issues.

Status Withdrawn Stopped before any participant enrolled.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Who can join Ages 18–45 · female only

Timeline Started 2021-03 · est. completion 2026-11

What this study is testing ClinicalTrials.gov NCT04683237 ↗

Description as written by the study sponsor.

To investigate the efficacy of liraglutide plus megestrol acetate in obesity patients with atypical endometrial hyperplasia (AEH)

Treatments tested

Liraglutide Injection also known as victoza, Nuo he li Drug

Initiate liraglutide with a dose of 0.6 mg daily for one week. After one week at 0.6 mg per day, increase the dose to 1.2 mg daily in a week, and increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg daily dose. If the patients can not tolerate 1.8mg per day, decrease the dose to the max tolerable dose.
Megestrol Acetate 160 MG also known as Yi li zhi, Megace Drug

160mg po qd

Main thing measured	Pathological complete response (CR) rates
Sponsor	Xiaojun Chen
Conditions studied	Atypical Endometrial Hyperplasia, Obese, Fertility Issues
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04683237 ↗